OncoMatch/Clinical Trials/NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Is NCT06056830 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies 64Cu-SAR-bisPSMA for prostate cancer.
Treatment: 64Cu-SAR-bisPSMA — The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage ≥T3A (NCCN)
Grade: ≥4 (Grade Group)
High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA >20 ng/mL)
Prior therapy
Cannot have received: high energy (>300 KeV) gamma-emitting radioisotope
Exception: within 5 physical half-lives prior to Day 1
Administration of any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham Hospital · Birmingham, Alabama
- Mayo Clinic- Phoenix · Phoenix, Arizona
- Urology Group of Southern California · Los Angeles, California
- Greater Los Angeles VA Medical Center · Los Angeles, California
- Stanford University Medical Center · Stanford, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify